IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in...
IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...
– Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.